Table 2.
Radiation Enhancement Ratio for 17-AAG, Celecoxib, or Combined Drug Treatment at SF0.1 and SF0.25 in Cancer Cells and Normal Bronchial Epithelial BEAS-2B Cells
| Cell line | 17-AAG (IC50) | Celecoxib (≤IC10) | Combined | |
|---|---|---|---|---|
| SF0.1 | A549 | 1.05±0.04 | 1.02±0.08 | 1.44±0.04 |
| MOR-P | 1.00±0.01 | 1.00±0.00a | 1.42±0.04 | |
| NCI-H460 | 1.06±0.11 | 1.02±0.01 | 1.59±0.06 | |
| HCT-116 | 1.07±0.03a | 1.00±0.00 | 1.32±0.01 | |
| BEAS-2B | 1.04±0.02 | 1.01±0.01 | 1.06±0.02 | |
| SF0.25 | A549 | 1.11±0.06 | 1.03±0.10 | 1.72±0.08 |
| MOR-P | 1.00±0.00 | 0.97±0.02a | 1.68±0.01 | |
| NCI-H460 | 1.11±0.13 | 1.03±0.02 | 1.88±0.04 | |
| HCT-116 | 1.02±0.01a | 1.00±0.00 | 1.53±0.02 | |
| BEAS-2B | 1.07±0.01 | 1.00±0.00 | 1.15±0.03 |
a
IC25, normal BEAS-2B cells were treated with 2.5 nM 17-AAG or 20 μM celecoxib, the highest concentrations among IC50 or IC25 values of each drug for cancer cells.